Fall IPO flurry as biotechs ramp up listing timelines

Four biotechs set terms for U.S. IPOs Monday in a month that has already seen five go public, including the largest raise of the year. Collectively, the quartet could raise over $500 million.

ADC Therapeutics S.A. proposed to sell 8.2 million shares at $23-$26 in an offering on the New York Stock Exchange. At the $24.50 midpoint, ADC would raise $200 million and be valued at $1.8 billion.

The antibody-drug conjugate company's pipeline includes three candidates to treat

Read the full 763 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE